Researcher
Jurgen Joossens
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Tech Transfer Office (TTO) (Research group)
Responsible
From1 Nov 2016 → Today - Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2005 → 31 Oct 2016
Projects
1 - 10 of 22
- SkillsApp, market exploration and validation of innovative web application to objectify skills evaluation.From1 May 2024 → TodayFunding: IOF - technology validation in lab
- AI-driven optimalisation of the user experience (UX) of digital tools.From1 Sep 2023 → TodayFunding: IOF - technology concept exploration
- CremAN: Simulating Input/Output and CAN communication for testing remanufactured automotive parts.From1 May 2023 → TodayFunding: IOF - technology concept exploration
- Optimization of the cryopreservation procedure of cells for therapeutic and research applications using Design of Experiments.From1 Jan 2023 → 31 Dec 2023Funding: IOF - technology concept exploration
- IOF Alliance Valorisation Manager UAntwerpen - UZAFrom7 Nov 2022 → TodayFunding: IOF - mandates
- IOF Valorisation Life SciencesFrom7 Mar 2022 → TodayFunding: IOF - mandates
- Development of a cascading approach for zero-waste valorization of agricultural and food residues.From1 Dec 2021 → 30 Nov 2023Funding: IOF - technology concept exploration
- IOF Valorisation - Project DevelopmentFrom1 Jul 2021 → TodayFunding: IOF - mandates
- Towards integrated Practices of Schools, Reception Centres and Leisure Time Facilities for Refugee Children: an Action Research.From1 May 2021 → 30 Apr 2023Funding: IOF - technology concept exploration
- IOF Valorisation of social and human sciences.From1 Mar 2021 → TodayFunding: IOF - mandates
Publications
1 - 10 of 50
- The effect of serine protease inhibitors on visceral pain in different rodent models with an intestinal insult(2022)
Authors: Hannah Ceuleers, Nikita Hanning, Michelle De bruyn, Joris De Man, Heiko De Schepper, Qian Li, Liansheng Liu, Steven Abrams, Annemieke Smet, Jurgen Joossens, et al.
Pages: 1 - 17 - Local colonic administration of a serine protease inhibitor improves post-inflammatory visceral hypersensitivity in rats(2021)
Authors: Nikita Hanning, Michelle De bruyn, Hannah Ceuleers, Tim Boogaerts, Maya Berg, Annemieke Smet, Heiko De Schepper, Jurgen Joossens, Alexander van Nuijs, Joris De Man, et al.
- The effect of a novel serine protease inhibitor on inflammation and intestinal permeability in a murine colitis transfer model(2021)
Authors: Hanne Van Spaendonk, Hannah Ceuleers, Annemieke Smet, Maya Berg, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Anne-Marie Lambeir, Joris De Man, Ingrid De Meester, et al.
Pages: 1 - 13 - A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation(2020)
Authors: Cedric Joossen, Adrienn Baán, Carlos Moreno Cinos, Jurgen Joossens, Nathalie Cools, Ellen Lanckacker, Lieve Moons, Kim Lemmens, Anne-Marie Lambeir, Erik Fransen, et al.
Pages: 1 - 14 - α-amino diphenyl phosphonates as novel inhibitors of Escherichia coli ClpP protease(2019)
Authors: Carlos Moreno Cinos, Elisa Sassetti, Irene Garcìa Salado, Gesa Witt, Siham Benramdane, Laura Reinhardt, Cristina D. Cruz, Jurgen Joossens, Pieter Van Der Veken, Heike Broetz-Oesterhe, et al.
Pages: 774 - 797 - The effect of pharmacological inhibition of Serine Proteases on neuronal networks in vitro(2019)
Authors: Sebastiaan Van De Vijver, Stephan Missault, Jeroen Van Soom, Pieter Van Der Veken, Koen Augustyns, Jurgen Joossens, Stefanie Dedeurwaerdere, Michele Giugliano
Pages: 1 - 23 - Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome(2018)
Authors: Hannah Ceuleers, Nikita Hanning, Leen Heirbaut, Samuel Van Remoortel, Jurgen Joossens, Pieter Van Der Veken, Sven Francque, Michelle De bruyn, Joris De Man, Jean-Pierre Timmermans, et al.
Pages: 3516 - 3533 - Novel triazine dimers with potent antitrypanosomal activity(2018)
Authors: Muthusamy Venkatraj, Irene Garcìa Salado, Jan Heeres, Jurgen Joossens, Guy Caljon, Louis Maes, Pieter Van Der Veken, Koen Augustyns
Pages: 306 - 319 - Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury(2017)
Authors: Sofie Martens, Manhyung Jeong, Wulf Tonnus, Friederike Feldmann, Sam Hofmans, Vera Goossens, Nozomi Takahashi, Jan Hinrich Braesen, Eun-Woo Lee, Pieter Van Der Veken, et al.
- Decreased levels of active uPA and KLK8 assessed by $\left[^{111}In\right]$MICA-401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy(2017)
Authors: Stephan Missault, Lore Peeters, Halima Amhaoul, David Thomae, Annemie Van Eetveldt, Barbara Favier, Anagha Thakur, Jeroen Van Soom, Asla Pitkanen, Koen Augustyns, et al.
Pages: 1615 - 1625
Patents
1 - 10 of 10
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- Triazines with suitable spacers for treatment and/or prevention of HIV infections (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)